Drug Profile
Tinostamustine - Mundipharma EDO
Alternative Names: Bendamustine-vorinostat fusion molecule; EDO S101; NL-101Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Northlake International
- Developer Cantonal Hospital of St Gallen; Mundipharma EDO
- Class Antineoplastics; Benzimidazoles; Small molecules
- Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma; Solid tumours
- Phase I Glioblastoma; Haematological malignancies; Malignant melanoma
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase I trials for Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 20 Oct 2023 Adverse events and efficacy data from a phase I trial in melanoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 06 Oct 2023 Tinostamustine is still in phase I development for Glioblastoma in USA (IV, Infusion) (NCT03452930)